Clinical Trials Logo

Non-Small Cell Lung Cancer clinical trials

View clinical trials related to Non-Small Cell Lung Cancer.

Filter by:

NCT ID: NCT00271271 Completed - Clinical trials for Non Small Cell Lung Cancer

Efficacy Study of GEMOX Combination and Vinorelbine in NSCL Patients

GON
Start date: June 2003
Phase: Phase 2
Study type: Interventional

Primary: ·To evaluate the activity of the combination of gemcitabine, oxaliplatin and vinorelbine as first line treatment in patients with non-small cell bronchopulmonary cancer Secondary: ·To evaluate the toxicity of the combination

NCT ID: NCT00269152 Completed - Clinical trials for Non-Small Cell Lung Cancer

Feasibility Study of Pemetrexed in Combination With Cisplatin or Carboplatin as Adjuvant Treatment of Non-Small Cell Lung Cancer

Start date: December 2005
Phase: Phase 2
Study type: Interventional

This study is a multicenter, open-label, two-arm, randomized, parallel Phase 2 feasibility study of pemetrexed in combination with either cisplatin (Arm A) or carboplatin (Arm B) as adjuvant combination-chemotherapy in participants with completely resected, stage Ib or IIa/IIb non-small cell lung cancer (NSCLC). A two-stage design will be employed independently for both treatment arms, with the possibility of stopping each treatment early for lack of feasibility.

NCT ID: NCT00268970 Completed - Clinical trials for Non-small Cell Lung Cancer

Satraplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer

Start date: December 2005
Phase: Phase 2
Study type: Interventional

The purpose of this trial is to study the combination regimen of satraplatin and paclitaxel in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC).

NCT ID: NCT00268255 Withdrawn - Clinical trials for Non-small Cell Lung Cancer

Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer

Start date: n/a
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Gefitinib may make tumor cells more sensitive to radiation therapy. Giving gefitinib together with radiation therapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of radiation therapy when given together with gefitinib and to see how well they work in treating patients with inoperable stage I or stage II non-small cell lung cancer.

NCT ID: NCT00265694 Recruiting - Clinical trials for Non-Small Cell Lung Cancer

Random Trial for Elderly Patients With NSCLC

Start date: n/a
Phase: Phase 3
Study type: Interventional

1. Recently a radomized trial of vinorelbine versus best supportive care in patients at 70 years of age or older demonstrated a definite improvement in overall survival rate and quality of life with chemotherapy. 2. The role of combination therapy containing the platinum compound, which is the standard therapy for the young patients is still vague. 3. Gemcitabine and carboplatin have favorable toxicity profile.

NCT ID: NCT00265603 Terminated - Clinical trials for Non-Small Cell Lung Cancer

Safety Study: Combined Modality Treatment for Non-Small Cell Lung Cancer

Start date: October 2004
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety of using a treatment called transimmunization in addition to standard therapy (radiation) in the treatment of lung cancer. Transimmunization is a treatment of the blood designed to boost the immune response against lung cancer. Transimmunization uses a device called a UVAR-XTS instrument, to remove a portion of blood, part of which is returned, and part of which is incubated overnight before being returned to the bloodstream the next day.

NCT ID: NCT00264134 Terminated - Clinical trials for Non-small Cell Lung Cancer

Docetaxel, Irinotecan, and Carboplatin in Extensive Stage Non-Small Cell Lung Cancer

Start date: June 2003
Phase: Phase 1/Phase 2
Study type: Interventional

Primary Objective: To determine the maximum tolerated dose of docetaxel when given with Irinotecan and Carboplatin for the treatment of inoperable lung cancer. Secondary Objective: To evaluate the dose-related toxicities of this triple regimen in patients with inoperable lung cancer.

NCT ID: NCT00260026 Completed - Clinical trials for Non-Small Cell Lung Cancer

Safety and Pharmacokinetics of Jin Fu Kang in Comb w/Docetaxel for Patients w/Non-Small Cell Lung Cancer

Start date: November 2004
Phase: Phase 2
Study type: Interventional

Researchers from Memorial Sloan-Kettering Cancer Center are conducting a research study on a Chinese herbal medicine known as "Jin Fu Kang". We want to see if this can help patients with advanced lung cancer. Jin Fu Kang might reduce the growth of cancer or improve quality of life. You are eligible for this trial because your cancer has progressed after prior chemotherapy and your doctor has recommended further chemotherapy treatment. Lung cancer that has been confirmed and that has spread is called advanced cancer. There is no known permanent cure for advanced lung cancer, but chemotherapy may temporarily shrink the cancer and improve the quality of patients' lives.

NCT ID: NCT00259675 Completed - Clinical trials for Non Small Cell Lung Cancer

Alternating Cycles of Carboplatin/Gemcitabine and Carboplatin/Taxol for Advanced Stage NSCLC

Start date: May 2004
Phase: Phase 2
Study type: Interventional

To see the efficacy of using chemotherapies alternatively (carboplatin and gemcitabine alternating with carboplatin and taxol) for pts with stage IIIB (nonresectable and stage IV NSCLC.

NCT ID: NCT00259285 Terminated - Clinical trials for Non-Small-Cell Lung Cancer

Pemetrexed and Cisplatin Treatment Before Surgery in Non Small Cell Lung Cancer

Start date: November 2005
Phase: Phase 2
Study type: Interventional

To determine the response to this regimen for therapy prior surgery in patients with locally advanced disease or metastatic disease.